|Mr. Iain Gladstone Ross BSc (Hons), C.DIR, CH.D||Exec. Chairman||92k||N/A||1954|
|Dr. Rob Quinn||CFO & Sec.||N/A||N/A||N/A|
|Dr. Barbara A. Ruskin||Sr. VP, Gen. Counsel & Chief Patent Officer||N/A||N/A||N/A|
|Ms. Linnea Elrington||VP & Head of HR||N/A||N/A||N/A|
|Dr. Mark Cameron||Head of Chemistry||N/A||N/A||N/A|
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Silence Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.